NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study

NCT04233372

CompletedPhase 4

Sponsor: Hospital Clinic of Barcelona

Conditions: Hiv

Interventions: Delstrigo

Countries: France, Spain

Subjects who go to emergency room for possible contact to HIV transmission receive Delstrigo as post exposition prophylaxis.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Subjects attending emergency room due to potential HIV exposition of either sex:
* Aged 18 years or more.
* Who have been exposed to non-occupational HIV and who meet the prerequisites for the current recommendations to begin prophylaxis post-exposition with three antiretroviral drugs.
* Who after being fully informed, give their written consent to participate in the study and undergo the tests and examinations required.
* Individuals able to do follow up correctly.

Exclusion Criteria:

* Pregnant women or nursing mothers or women trying to conceive during the study period.
* Patients in whom it is known or suspected that the source case has a resistance to one of the drugs from the study treatment regimens.
* Treatment with drugs that are contraindicated in the study or products that are in the investigational phase.
* Allergic reactions or intolerance to the compounds of the study treatment regiments

Locations (2)

Nantes, France
Barcelona, Spain